Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Reexamination Certificate
2011-01-18
2011-01-18
Shameem, Golam M. M. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
C562S507000
Reexamination Certificate
active
07872046
ABSTRACT:
A crystalline form of a (3S)-aminomethyl-5-hexanoic acid prodrug and methods of preparing a crystalline form of a (3S)-aminomethyl-5-hexanoic acid prodrug, and methods of using a crystalline form of a (3S)-aminomethyl-5-hexanoic acid prodrug are provided.
REFERENCES:
patent: 4024175 (1977-05-01), Satzinger et al.
patent: 4126684 (1978-11-01), Robson et al.
patent: 4760057 (1988-07-01), Alexander
patent: 4916230 (1990-04-01), Alexander
patent: 5006560 (1991-04-01), Kreutner et al.
patent: 5563175 (1996-10-01), Silverman et al.
patent: 5684018 (1997-11-01), Alexander
patent: 5719185 (1998-02-01), Bountra et al.
patent: 6020370 (2000-02-01), Horwell et al.
patent: 6028214 (2000-02-01), Silverman et al.
patent: 6103932 (2000-08-01), Horwell et al.
patent: 6117906 (2000-09-01), Silverman et al.
patent: 6117908 (2000-09-01), Andrews et al.
patent: 6562865 (2003-05-01), Codd et al.
patent: 6818787 (2004-11-01), Gallop et al.
patent: 6927036 (2005-08-01), Gallop et al.
patent: 6972341 (2005-12-01), Gallop et al.
patent: 7026351 (2006-04-01), Gallop et al.
patent: 7109239 (2006-09-01), Gallop et al.
patent: 7186855 (2007-03-01), Gallop et al.
patent: 7227028 (2007-06-01), Gallop et al.
patent: 7232924 (2007-06-01), Raillard et al.
patent: 7300956 (2007-11-01), Gallop et al.
patent: 2004/0176456 (2004-09-01), Taylor et al.
patent: 2004/0254246 (2004-12-01), Barrett et al.
patent: 2005/0070483 (2005-03-01), Donevan et al.
patent: 2005/0090550 (2005-04-01), Barrett
patent: 2005/0153946 (2005-07-01), Hirsh et al.
patent: 2005/0192353 (2005-09-01), Barrett et al.
patent: 2008/0161393 (2008-07-01), Barrett et al.
patent: 2 374 595 (2002-10-01), None
patent: WO 92/09560 (1992-06-01), None
patent: WO 93/23383 (1993-11-01), None
patent: WO 97/29101 (1997-08-01), None
patent: WO 97/33858 (1997-09-01), None
patent: WO 97/33859 (1997-09-01), None
patent: WO 98/17627 (1998-04-01), None
patent: WO 99/08670 (1999-02-01), None
patent: WO 99/08671 (1999-02-01), None
patent: WO 99/21824 (1999-05-01), None
patent: WO 99/31057 (1999-06-01), None
patent: WO 99/31074 (1999-06-01), None
patent: WO 99/31075 (1999-06-01), None
patent: WO 99/61424 (1999-12-01), None
patent: WO 00/15611 (2000-03-01), None
patent: WO 00/31020 (2000-03-01), None
patent: WO 00/50027 (2000-08-01), None
patent: WO 00/61135 (2000-10-01), None
patent: WO 01/08675 (2001-02-01), None
patent: WO 01/13904 (2001-03-01), None
patent: WO 01/26638 (2001-04-01), None
patent: WO 02/00209 (2002-01-01), None
patent: WO 02/096404 (2002-12-01), None
patent: WO 02/100347 (2002-12-01), None
patent: WO 2004/054565 (2004-07-01), None
patent: WO 2005/010011 (2005-02-01), None
patent: WO 2005/025563 (2005-03-01), None
patent: WO 2005/089872 (2005-09-01), None
patent: WO 2007/027476 (2007-03-01), None
patent: WO 2007/027477 (2007-03-01), None
patent: WO 2007/052999 (2007-05-01), None
patent: WO 2009/061934 (2009-05-01), None
patent: WO 2009/061934 (2009-05-01), None
Brittain et al. “Polymorphism in Pharmaceutical Dosage Forms.” Polymorphism in Pharmaceutical Solids XX (Jan. 1999). pp. 235-238 and 348-361.
Morissette et al. “High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids.” Advanced Drug Delivery Reviews 2004, 56, 275-300.
Vippagunta, Sudha R. “Crystalline Solids.” Advanced Drug Delivery Reviews 48(2001): 3-26.
U.S. Appl. No. 10/266,169, filed Nov. 6, 2008, Benson et al.
U.S. Appl. No. 61/023,808, filed Jan. 25, 2008, Yao et al.
U.S. Appl. No. 61/023,813, filed Jan. 25, 2008, Yao et al.
U.S. Appl. No. 61/121,859, filed Dec. 11, 2008, Gallop et al.
Alexander et al., (Acyloxy)alkyl carbamate prodrugs of norfloxacin.J. Med. Chem. 1991, 34(1), 78-81.
Alexander et al., (Acyloxy)alkyl carbamates as novel bioreversible prodrugs for amines: increased permeation through biological membranes.J. Med. Chem. 1988, 31(2), 318-322.
Becker et al., Pregabalin is effective against behavioural and electrographic seizures during alcohol withdrawal.Alcohol&Alcoholism2006, 41(4), 399-406.
Ben-David et al., Gabapentin therapy for vulvodynia.Anesth, Analg. 1999, 89, 1459-60.
Blommel and Blommel, Pregabalin: an antiepileptic agent useful for neuropathic pain.Am J Health Syst Pharm2007, 64(14), 1475-82.
Bowsher, Neurogenic pain syndromes and their management.Br. Med. Bull. 1991, 47(3), 644-66.
Bryans et al., 3-Substituted GABA analogs with central nervous system activity: a review.Med. Res. Rev. 1999, 19(2), 149-177.
Bryans et al., Identification of novel ligands for the gabapentin binding site on the α2δ subunit of a calcium channel and their evaluation as anticonvulsant agents.J. Med. Chem. 1998, 41, 1838-1845.
Buvanendran et al., Preoperative cyclooxygenase-2 inhibitor treatment reduces the incidence of heterotopic ossification after hip arthroplasty: six-month follow-up. Anesthesiology 2007, 107(2), 358-359.
Ciccaglione and Marzio, Effect of acute and chronic administration of the GABABagonist baclofen on 24 hour pH metry and symptoms in control subjects and in patients with gastro-oesophageal reflux disease.Gut2003, 52, 464-70.
Codd et al., Tramadol and several anticonvulsants synergize in attenuating nerve injury-induced allodynia.Pain2008, 134, 254-262.
Coluzzi and Mattia, Chronic non-cancer pain: focus on once-daily tramadol formulations.Ther Clin Risk Manage2007, 3(5), 819-29.
Crofford et al., Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial.Arthritis and Rheumatism2005, 52(4), 1264-73.
Dahl et al., Protective premedication: an option with gabapentin and related drugs? A review of gabapentin and pregabalin in the treatment of post—operative pain.Acta Anesthesiol Scand2004, 48(8), 1130-36.
Dapas et al., Baclofen for the treatment of acute low-back syndrome—a double-blind comparison with placebo.Spine1985, 10(4), 345-9.
Freedman and O'Hara, Pregabalin has opioid-sparing effects following augmentation mamaplasty.Aesthetic Surgery J2008, 28(4), 421-424.
Freitag, Preventative treatment for migraine and tension-type headaches: do drugs having effects on muscle spasm and tone have a role?CNS Drugs2003, 17(6), 373-81.
Freynhagen et al., Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomized, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens.Pain2005, 115(3), 254-63.
Fromm et al., Role of inhibitory mechanisms in trigeminal neuralgia.Neurology1981, 31, 683-7.
Gatti et al., Controlled-release oxycodone and pregabalin in the treatment of neuropathic pain: results of a multicenter Italian study.Eur Neurol2009, 61, 129-137.
Gilron, Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions.Curr Opin Anaesthesiol2007, 20, 456-472.
Gogate et al., N-(Acyloxyalkoxycarbonyl) derivatives as potential prodrugs of amines. I. Kinetics and mechanism of degradationin aqueous solutions.International Journal of Pharmaceutics1987, 40, 235-248.
Grond and Sablotzky, Clinical pharmacology of tramadol.Clin Pharmacokinet2004, 43(13), 879-923.
Guttuso et al., Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial.Obstet. Gynecol. 2003, 101(2), 337-345.
Guttuso, Gabapentin's effects on hot flashes and hypothermia.Neurology2000, 54, 2161-2163.
Hanna et al., Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients.Eur J Pain2008, 12, 804-13.
Heiss and Gais, Polyethylene glycol monomethyl ether-modified pig liver esterase: preparation, characterization and catalysis of enantioselective hydrolysis in water and acylation in organic solvents.Tetrahedron Lett. 1995, 36(22), 3833-3836.
Hindmarch et al., A double-blind study in healthy volunteers to assess the effects on sleep of pregabalin compared with alprazolam and placebo.Sleep2005, 28(2), 187-93.
Jeffery et al., Gabapentin for hot flashes in prostate cancer.Ann. Pharmacother. 2002, 36(3), 433-436.
Jokela et al., A randomized controlled trial of perio
Barrett Ronald W.
Gallop Mark A.
Virsik Peter A.
Yao Fenmei
Dorsey & Whitney LLP
Otton Alicia L
Shameem Golam M. M.
XenoPort, Inc.
LandOfFree
Crystalline form of a (3S)-aminomethyl-5-methyl-hexanoic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Crystalline form of a (3S)-aminomethyl-5-methyl-hexanoic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Crystalline form of a (3S)-aminomethyl-5-methyl-hexanoic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2675387